Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism.
Substance P analogues including [d-Arg1,d-Phe5,d-Trp7,9,Leu11]substance P (SpD) act as "broad spectrum neuropeptide antagonists" and are potential anticancer agents that inhibit the growth of small cell lung cancer cells in vitro and in vivo. However, their mechanism of action is controversial and not fully understood. Although these compounds block bombesin-induced mitogenesis and signal transduction, they also have agonist activity. The mechanism underlying this agonist activity was examined. SpD binds to the ligand-binding site of the bombesin/gastrin-releasing peptide receptor and blocks the bombesin-stimulated increase in [Ca2+]i within the same concentration range that causes sustained activation of c-Jun N-terminal kinase and extracellular signal-regulated protein kinase (ERK). The activation of c-Jun N-terminal kinase by SpD and bombesin is blocked by dominant negative inhibition of G(alpha12). The ERK activation by SpD is pertussis toxin-sensitive in contrast to ERK activation by bombesin, which is pertussis toxin-insensitive but dependent on epidermal growth factor receptor phosphorylation. SpD does not simply act as a partial agonist but differentially modulates the activation of the G-proteins G(alpha12), G(i), and G(q) compared with bombesin. This unique ability allows the bombesin receptor to couple to G(i) and at the same time block receptor activation of G(q). Our results provide direct evidence that SpD is acting as a "biased agonist" and that this has physiological relevance in small cell lung cancer cells. This validation of the concept of biased agonism has important implications in the development of novel pharmacological agents to dissect receptor-mediated signal transduction and of highly selective drugs to treat human disease.
MacKinnon
A C
AC
Rayne Laboratory, Centre for Inflammation Research, Respiratory Medicine Unit, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 9AG, United Kingdom.
Waters
C
C
Jodrell
D
D
Haslett
C
C
Sethi
T
T
D016475:3T3 Cells; D000818:Animals; D001665:Binding Sites; D015153:Blotting, Western; D001839:Bombesin / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D019556:COS Cells; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000737:chemistry* / Q000378:metabolism*; D005799:Genes, Dominant; D006801:Humans; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008962:Models, Theoretical; D037342:Pertussis Toxin; D010766:Phosphorylation; D011485:Protein Binding; D011799:Quinazolines; D051381:Rats; D018004:Receptors, Bombesin / Q000737:chemistry / Q000378:metabolism*; D015398:Signal Transduction; D013373:Substance P / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D020032:Tyrphostins / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D004791:Enzyme Inhibitors; D008024:Ligands; D011799:Quinazolines; D018004:Receptors, Bombesin; D020032:Tyrphostins; D010566:Virulence Factors, Bordetella; C101044:RTKI cpd; D013373:Substance P; D037342:Pertussis Toxin; D020928:Mitogen-Activated Protein Kinases; D019204:GTP-Binding Proteins; D001839:Bombesin; D002118:Calcium